The 'all comer' coroflex please drug-eluting stent registry in europe and asia e an overall and transcontinental assessment of the 10-month major adverse cardiac events

Matthias Leschke, Vo Thanh Nhan, Matthias Waliszewski, Vicente Palacios, I. Horváth, Vladimir A. Ivanov, Damras Tresukosol, Panicos Avraamides, André Schneider, Martin Unverdorben

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: Randomized trials assess the potential of a medical device in well defined indications while "all comer studies" reveal the device performance in the real clinical environment. Aims: This 'all comers' registry assessed the 10-month outcome of the Coroflex® Please drug-eluting stent in Europe and Asia by clinically driven major adverse cardiac events. Methods: The Coroflex® Please Registry was an international, prospective, multicenter registry enrolling patients with symptomatic ischemic heart disease. The primary endpoint was clinically driven target lesion revascularization (TLR) at 9 months. Secondary endpoints were technical success, in-hospital outcomes, definite stent thrombosis and major adverse cardiac events (death, myocardial infarction, or TLR) for subgroup analyses. Results: Of the enrolled 1230 patients (63. 6 ± 11. 2 years, 33. 9% diabetics), 339 (27. 6%) had an acute coronary syndrome, 148 (12. 1%) STEMI and 191 (15. 6%) NSTEMI. After 10. 5 ± 3. 8 months (follow-up rate 92. 8%), the target lesion revascularization rate (TLR) was 7. 8% overall, 8. 3% in STEMI, and 11. 3% in NSTEMI patients. Total MACE was 11. 1% and signifi- cantly higher in ACS with either diabetes mellitus (22. 9%, p = 0. 017) or age ≥ 75 years (25. 4%, p = 0. 026). In European and Asian patients MI rates (5. 2% vs 3. 1%, p = 0. 135) and cardiac death rates (1. 6% vs 0. 9%, p = 0. 414) were similar. The MACE rate was higher in Europe (13. 6% vs 4. 7%, p <0. 001) driven by a six times higher TLR rate.

Original languageEnglish
Pages (from-to)453-461
Number of pages9
JournalIndian Heart Journal
Volume64
Issue number5
DOIs
Publication statusPublished - Sep 2012

Fingerprint

Drug-Eluting Stents
Registries
Equipment and Supplies
Acute Coronary Syndrome
Stents
Myocardial Ischemia
Diabetes Mellitus
Thrombosis
Myocardial Infarction
Mortality
Non-ST Elevated Myocardial Infarction
ST Elevation Myocardial Infarction

Keywords

  • Drug-eluting stent
  • MACE
  • Percutaneous coronary intervention
  • Predictor
  • Risk factors

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

The 'all comer' coroflex please drug-eluting stent registry in europe and asia e an overall and transcontinental assessment of the 10-month major adverse cardiac events. / Leschke, Matthias; Nhan, Vo Thanh; Waliszewski, Matthias; Palacios, Vicente; Horváth, I.; Ivanov, Vladimir A.; Tresukosol, Damras; Avraamides, Panicos; Schneider, André; Unverdorben, Martin.

In: Indian Heart Journal, Vol. 64, No. 5, 09.2012, p. 453-461.

Research output: Contribution to journalArticle

Leschke, M, Nhan, VT, Waliszewski, M, Palacios, V, Horváth, I, Ivanov, VA, Tresukosol, D, Avraamides, P, Schneider, A & Unverdorben, M 2012, 'The 'all comer' coroflex please drug-eluting stent registry in europe and asia e an overall and transcontinental assessment of the 10-month major adverse cardiac events', Indian Heart Journal, vol. 64, no. 5, pp. 453-461. https://doi.org/10.1016/j.ihj.2012.08.002
Leschke, Matthias ; Nhan, Vo Thanh ; Waliszewski, Matthias ; Palacios, Vicente ; Horváth, I. ; Ivanov, Vladimir A. ; Tresukosol, Damras ; Avraamides, Panicos ; Schneider, André ; Unverdorben, Martin. / The 'all comer' coroflex please drug-eluting stent registry in europe and asia e an overall and transcontinental assessment of the 10-month major adverse cardiac events. In: Indian Heart Journal. 2012 ; Vol. 64, No. 5. pp. 453-461.
@article{d16ff605a78d40cc8fe3e308a274b084,
title = "The 'all comer' coroflex please drug-eluting stent registry in europe and asia e an overall and transcontinental assessment of the 10-month major adverse cardiac events",
abstract = "Background: Randomized trials assess the potential of a medical device in well defined indications while {"}all comer studies{"} reveal the device performance in the real clinical environment. Aims: This 'all comers' registry assessed the 10-month outcome of the Coroflex{\circledR} Please drug-eluting stent in Europe and Asia by clinically driven major adverse cardiac events. Methods: The Coroflex{\circledR} Please Registry was an international, prospective, multicenter registry enrolling patients with symptomatic ischemic heart disease. The primary endpoint was clinically driven target lesion revascularization (TLR) at 9 months. Secondary endpoints were technical success, in-hospital outcomes, definite stent thrombosis and major adverse cardiac events (death, myocardial infarction, or TLR) for subgroup analyses. Results: Of the enrolled 1230 patients (63. 6 ± 11. 2 years, 33. 9{\%} diabetics), 339 (27. 6{\%}) had an acute coronary syndrome, 148 (12. 1{\%}) STEMI and 191 (15. 6{\%}) NSTEMI. After 10. 5 ± 3. 8 months (follow-up rate 92. 8{\%}), the target lesion revascularization rate (TLR) was 7. 8{\%} overall, 8. 3{\%} in STEMI, and 11. 3{\%} in NSTEMI patients. Total MACE was 11. 1{\%} and signifi- cantly higher in ACS with either diabetes mellitus (22. 9{\%}, p = 0. 017) or age ≥ 75 years (25. 4{\%}, p = 0. 026). In European and Asian patients MI rates (5. 2{\%} vs 3. 1{\%}, p = 0. 135) and cardiac death rates (1. 6{\%} vs 0. 9{\%}, p = 0. 414) were similar. The MACE rate was higher in Europe (13. 6{\%} vs 4. 7{\%}, p <0. 001) driven by a six times higher TLR rate.",
keywords = "Drug-eluting stent, MACE, Percutaneous coronary intervention, Predictor, Risk factors",
author = "Matthias Leschke and Nhan, {Vo Thanh} and Matthias Waliszewski and Vicente Palacios and I. Horv{\'a}th and Ivanov, {Vladimir A.} and Damras Tresukosol and Panicos Avraamides and Andr{\'e} Schneider and Martin Unverdorben",
year = "2012",
month = "9",
doi = "10.1016/j.ihj.2012.08.002",
language = "English",
volume = "64",
pages = "453--461",
journal = "Indian Heart Journal",
issn = "0019-4832",
publisher = "Cardiology Society of India",
number = "5",

}

TY - JOUR

T1 - The 'all comer' coroflex please drug-eluting stent registry in europe and asia e an overall and transcontinental assessment of the 10-month major adverse cardiac events

AU - Leschke, Matthias

AU - Nhan, Vo Thanh

AU - Waliszewski, Matthias

AU - Palacios, Vicente

AU - Horváth, I.

AU - Ivanov, Vladimir A.

AU - Tresukosol, Damras

AU - Avraamides, Panicos

AU - Schneider, André

AU - Unverdorben, Martin

PY - 2012/9

Y1 - 2012/9

N2 - Background: Randomized trials assess the potential of a medical device in well defined indications while "all comer studies" reveal the device performance in the real clinical environment. Aims: This 'all comers' registry assessed the 10-month outcome of the Coroflex® Please drug-eluting stent in Europe and Asia by clinically driven major adverse cardiac events. Methods: The Coroflex® Please Registry was an international, prospective, multicenter registry enrolling patients with symptomatic ischemic heart disease. The primary endpoint was clinically driven target lesion revascularization (TLR) at 9 months. Secondary endpoints were technical success, in-hospital outcomes, definite stent thrombosis and major adverse cardiac events (death, myocardial infarction, or TLR) for subgroup analyses. Results: Of the enrolled 1230 patients (63. 6 ± 11. 2 years, 33. 9% diabetics), 339 (27. 6%) had an acute coronary syndrome, 148 (12. 1%) STEMI and 191 (15. 6%) NSTEMI. After 10. 5 ± 3. 8 months (follow-up rate 92. 8%), the target lesion revascularization rate (TLR) was 7. 8% overall, 8. 3% in STEMI, and 11. 3% in NSTEMI patients. Total MACE was 11. 1% and signifi- cantly higher in ACS with either diabetes mellitus (22. 9%, p = 0. 017) or age ≥ 75 years (25. 4%, p = 0. 026). In European and Asian patients MI rates (5. 2% vs 3. 1%, p = 0. 135) and cardiac death rates (1. 6% vs 0. 9%, p = 0. 414) were similar. The MACE rate was higher in Europe (13. 6% vs 4. 7%, p <0. 001) driven by a six times higher TLR rate.

AB - Background: Randomized trials assess the potential of a medical device in well defined indications while "all comer studies" reveal the device performance in the real clinical environment. Aims: This 'all comers' registry assessed the 10-month outcome of the Coroflex® Please drug-eluting stent in Europe and Asia by clinically driven major adverse cardiac events. Methods: The Coroflex® Please Registry was an international, prospective, multicenter registry enrolling patients with symptomatic ischemic heart disease. The primary endpoint was clinically driven target lesion revascularization (TLR) at 9 months. Secondary endpoints were technical success, in-hospital outcomes, definite stent thrombosis and major adverse cardiac events (death, myocardial infarction, or TLR) for subgroup analyses. Results: Of the enrolled 1230 patients (63. 6 ± 11. 2 years, 33. 9% diabetics), 339 (27. 6%) had an acute coronary syndrome, 148 (12. 1%) STEMI and 191 (15. 6%) NSTEMI. After 10. 5 ± 3. 8 months (follow-up rate 92. 8%), the target lesion revascularization rate (TLR) was 7. 8% overall, 8. 3% in STEMI, and 11. 3% in NSTEMI patients. Total MACE was 11. 1% and signifi- cantly higher in ACS with either diabetes mellitus (22. 9%, p = 0. 017) or age ≥ 75 years (25. 4%, p = 0. 026). In European and Asian patients MI rates (5. 2% vs 3. 1%, p = 0. 135) and cardiac death rates (1. 6% vs 0. 9%, p = 0. 414) were similar. The MACE rate was higher in Europe (13. 6% vs 4. 7%, p <0. 001) driven by a six times higher TLR rate.

KW - Drug-eluting stent

KW - MACE

KW - Percutaneous coronary intervention

KW - Predictor

KW - Risk factors

UR - http://www.scopus.com/inward/record.url?scp=84870764956&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870764956&partnerID=8YFLogxK

U2 - 10.1016/j.ihj.2012.08.002

DO - 10.1016/j.ihj.2012.08.002

M3 - Article

VL - 64

SP - 453

EP - 461

JO - Indian Heart Journal

JF - Indian Heart Journal

SN - 0019-4832

IS - 5

ER -